CORDIS
EU research results

CORDIS

English EN
An integrated study on three novel regulatory hubs in megakaryocytes and platelets, discovered as risk genes for myocardial infarction by a genome-wide association and platelet systems biology study

An integrated study on three novel regulatory hubs in megakaryocytes and platelets, discovered as risk genes for myocardial infarction by a genome-wide association and platelet systems biology study

Objective

The overarching objective of the ITN is to offer an intercalated study environment for young and talented researchers in the field of coronary artery disease (CAD) research. 12 PhD fellows operating in a unique training environment will work as a multi-disciplinary team to perform research spanning the full spectrum from basic to translational to bring novel inventions to the bedside. The fellows will be mentored by world-leading experts to shape a new generation of European leaders in biomedical science and overcome current fragmentation in Europe. The research is at the forefront of biomedical science because of the UK genome-wide association study in 2000 myocardial infarction (MI) patients and our EU-FP6 integrated projects Bloodomics and Cardiogenics. We will exploit our knowledge about the genetic architecture of MI to investigate the hypothesis whether sequence variation of genes encoding network hubs poses a greater risk for network destabilisation compared to genes encoding regular nodes. Focusing on three hub genes we postulate that genetic/bio-markers associated with hubs can be integrated in algorithms for MI/CAD risk prediction. Success will critically depend on new developments in computing, machine learning, pattern recognition and advanced data mining and statistical analysis. To have a free development path from basic discovery to health care improvement young scientists must be taught to cross the classic barriers between academic disciplines. We offer a timely and necessary alternative to Europe’s classic PhD programmes by providing a seamlessly integrated multi-disciplinary environment in an academic-private sector partnership free of boundaries. Our aim is a targeted strategy for prevention and treatment based on a better understanding of the genetic and molecular mechanism of disease. This will deliver major advances in public health and patient care, which can only be achieved if a new scientific cadre is developed.

Coordinator

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

Address

Trinity Lane The Old Schools
Cb2 1tn Cambridge

United Kingdom

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 712 554

Administrative Contact

Dawn Edwards (Ms.)

Participants (9)

Sort alphabetically

Sort by EU Contribution

Expand all

Academisch Medisch Centrum bij de Universiteit van Amsterdam

Netherlands

EU Contribution

€ 261 382

ROBERT BOSCH GMBH

Germany

EU Contribution

€ 200 457

EUROPEAN MOLECULAR BIOLOGY LABORATORY

Germany

EU Contribution

€ 240 203

MEDICAL RESEARCH COUNCIL

United Kingdom

EU Contribution

€ 211 027

SYLVIA LAWRY CENTRE FOR MULTIPLE SCLEROSIS RESEARCH E.V.

Germany

EU Contribution

€ 397 166

TRIUM ANALYSIS ONLINE GMBH

Germany

EU Contribution

€ 200 457

TECHNISCHE UNIVERSITAET MUENCHEN

Germany

EU Contribution

€ 200 457

UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN

Ireland

EU Contribution

€ 216 654

GENOME RESEARCH LIMITED

United Kingdom

EU Contribution

€ 211 027

Project information

Grant agreement ID: 215820

Status

Closed project

  • Start date

    1 September 2008

  • End date

    31 August 2012

Funded under:

FP7-PEOPLE

  • Overall budget:

    € 2 851 384

  • EU contribution

    € 2 851 384

Coordinated by:

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

United Kingdom